Inventor · disambiguated record
Eric Gary Stefanich
Also filed as: STEFANICH ERIC · STEFANICH ERIC GARY
9 granted patents·15 pending applications·30 citations·filing 2009–2022
86Inventor score
Top patents by PatentIndex Score
24 records- 0195US9815880B2IL-22 Fc fusion proteinsGENENTECH INC·Filed 2016·Granted Nov 14, 2017·15 cites·18 claims
- 0291US10160793B2Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteinsGENENTECH INC·Filed 2014·Granted Dec 25, 2018·9 cites·30 claims
- 0390US10087227B2Nucleic acids encoding IL-22 Fc fusion proteinsGENENTECH INC·Filed 2016·Granted Oct 2, 2018·5 cites·26 claims
- 0481US11155591B2Methods of treating acute pancreatitis using IL-22 fc fusion proteinsGENENTECH INC·Filed 2018·Granted Oct 26, 2021·1 cites·27 claims
- 0578US2022349903A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGENENTECH INC·Filed 2021·Application pending·0 cites
- 0678US2023063741A1IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USEGENENTECH INC·Filed 2022·Application pending·0 cites
- 0771US11332507B2IL-22 Fc fusion proteinsGENENTECH INC·Filed 2018·Granted May 17, 2022·0 cites·13 claims
- 0871US11130791B2Methods for treating metabolic syndrome using IL-22 Fc fusion proteinsGENENTECH INC·Filed 2018·Granted Sep 28, 2021·0 cites·29 claims
- 0969US11136365B2Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteinsGENENTECH INC·Filed 2018·Granted Oct 5, 2021·0 cites·28 claims
- 1066US2010255508A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGELZLEICHTER THOMAS RICHARD·Filed 2009·Application pending·0 cites
- 1165US10584155B2Pharmaceutical compositions of IL-22 Fc fusion proteinsGENENTECH INC·Filed 2017·Granted Mar 10, 2020·0 cites·29 claims
- 1264US10544198B2Methods of accelerating or improving wound healing using IL-22 FC fusion proteinsGENENTECH INC·Filed 2017·Granted Jan 28, 2020·0 cites·40 claims
- 1363US2019310266A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGENENTECH INC·Filed 2018·Application pending·0 cites
- 1456US2013109032A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGENENTECH INC·Filed 2011·Application pending·0 cites
- 1556US2017102393A1Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonistsGENENTECH INC·Filed 2016·Application pending·0 cites
- 1653US2022403033A1Methods of administering beta7 integrin antagonistsGENENTECH INC·Filed 2022·Application pending·0 cites
- 1750US2010021460A1Methods of Treating Autoimmune Diseases Using CD4 AntibodiesGENENTECH INC·Filed 2009·Application pending·0 cites
- 1849US2018355009A1IL-22 Fc FUSION PROTEIN AND METHODS OF USEGENENTECH INC·Filed 2018·Application pending·0 cites
- 1946US2018346586A1Methods of treating cancer using anti-ox40 antibodiesGENENTECH INC·Filed 2018·Application pending·0 cites
- 2044US2021238288A1Methods of administering beta7 integrin antagonistsGENENTECH INC·Filed 2020·Application pending·0 cites
- 2144US2018256711A1Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonistsGENENTECH INC·Filed 2017·Application pending·0 cites
- 2240US2016355597A1Methods of treating cancer using anti-ox40 antibodiesGENENTECH INC·Filed 2016·Application pending·0 cites
- 2340US2017000885A1Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonistsGENENTECH INC·Filed 2016·Application pending·0 cites
- 2437US2014120084A1Methods of administering beta7 integrin antagonistsGENENTECH INC·Filed 2013·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →